TROVIS PHARMACEUTICALS LLC – Trademark Portfolio
Entity Type: 16
TROVIS PHARMACEUTICALS LLC holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include VIIBRYD. The owner is based in NEWTON, MA.
ONE GATEWAY CENTER, SUITE 702
NEWTON, MA 02458
Showing of trademarks Trademarks
Trademark Classifications
TROVIS PHARMACEUTICALS LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does TROVIS PHARMACEUTICALS LLC have?
TROVIS PHARMACEUTICALS LLC has 8 U.S. trademarks filed with the USPTO. Of these, 1 registered, 5 abandoned, 2 cancelled.
What trademark classes does TROVIS PHARMACEUTICALS LLC file in?
TROVIS PHARMACEUTICALS LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are TROVIS PHARMACEUTICALS LLC's most well-known trademarks?
TROVIS PHARMACEUTICALS LLC's registered trademark portfolio includes well-known marks such as VIIBRYD. These are among 1 currently registered trademark in the portfolio.
What is TROVIS PHARMACEUTICALS LLC's trademark registration success rate?
TROVIS PHARMACEUTICALS LLC has a 13% trademark registration rate, with 1 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.